I am a 62-year-old female who has focal segmental glomerulosclerosis (FSGS) that was diagnosed in 2001. After several years ...

There are two types of dialysis. Although most people think of center-based hemodialysis as the primary treatment for ...

Doing hemodialysis in a center is time-consuming, typically ranging from four hours three times per week, plus the ...

It is very likely you will continue to lose kidney function, so planning for kidney replacement therapy now is important. The ...

A majority (7/9 or 78%) of these consisted of p.R229Q, inherited together either with a rarer allele (n = 4), p.R138Q (n = 2 ... with type 2 diabetes had end-stage renal disease.

DEAR DR. ROACH: I am a 62-year-old female who has focal segmental glomerulosclerosis (FSGS) diagnosed in 2001. After several years of ...

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming ...

for treating primary membranous nephropathy (pMN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and a broader patient population with IgA nephropathy (IgAN).

Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney ...

Nevertheless, the company's pipeline still has another application for Sparsentan for focal segmental glomerulosclerosis ... and the HARMONY late-stage trial setback for the enzyme replacement ...